High prevalence of such diseases is expected to boost the growth of global ablation devices market
Over the course of the predicted period, the prevalence of
various chronic diseases, such as cancer and cardiovascular disorders, will
increase globally. The prevalence of cancer has significantly increased during
the previous few years. The majority of cancer patients who undergo
radiofrequency ablation had tumours with a diameter of less than 1.5 inches.
Thus, an increase in cases and the effectiveness of ablation operations will
have a beneficial effect on business growth.
Thermal and nonthermal technologies make up the bulk of the
market for ablation devices. Electrical, radiation, radio frequency, light,
ultrasound, microwave, and hydrothermal are other categories for thermal
technology. Cryotherapy and hydromechanical are two market segments for
nonthermal technology. On the basis of the goods offered for in-depth study of
technology markets during the analysis period, the ablation devices technology
market is further categorised. The market report goes into great detail on
technology that is based on procedures and its further effects on the
therapeutic field. For the time period, these two segmentations are also
covered in detail. Geographically, the market is divided into North America,
Europe, Asia-Pacific, and ROW.
During the forecast period, rising acquisitions, mergers,
and partnerships by key players are anticipated to fuel the expansion of the worldwide
ablation devices market. For instance, the maker of radiofrequency
ablation (RFA) systems Cosman Medical, Inc., was bought by Boston Scientific
Corporation in 2016. With this acquisition, Boston Scientific's offering of
deep brain stimulation systems and spinal cord stimulators has grown even more.
Furthermore, in 2015, Quanta System, a renowned producer of medical lasers for
surgical purposes, and EDAP TMS announced a global strategic OEM relationship.
Through this collaboration, Quanta produces specialised urology stone lasers
that will be marketed under the EDAP name. Furthermore, in 2013, Abbott
Laboratories bought IDEV Technologies, a privately held business that
specialised in creating cutting-edge medical gadgets for the use of ablation
catheters in electrophysiology.
Comments
Post a Comment